An anonymous director reports

UPDATE ON CHINOOK'S INVESTMENTS IN GERMANY

Chinook Tyee Industry Ltd. is an investment finance company with two European subsidiaries -- AMP Alternative Medical Products GmbH based in Erfurt, Germany, and Mercury Partners & Company PLC based in Valletta, Malta. Chinook has 10,217,796 fully diluted shares issued and outstanding and net investment assets of over $2-million (unaudited) as of Sept. 30, 2018.

About AMP Alternative Medical Products GmbH

AMP Alternative Medical Products is a biopharmaceutical company based in the German state of Thuringia and provides medical cannabis formulations and dose delivery systems for German patients.

Since March, 2017, German doctors can prescribe medical cannabis to patients suffering from serious illnesses which patients can get filled by pharmacists and generally paid for by German health insurance companies. AMP's business involves the purchase of EU-GMP (European Union good manufacturing practice) medical cannabis from third party suppliers and arranging transportation, logistics and storage services for ultimate distribution through pharmaceutical distributors to pharmacists in Germany.

According to analytics firm Prohibition Partners at the 2019 Davos World Economic Forum, Europe's three largest medical cannabis markets -- Germany, the Netherlands and Italy -- could double in size in 2019, making this a transformative year for the European market.

In Canada, licensed producers of cannabis that enter into supply contracts with AMP are audited to ensure they meet EU-GMP standards before AMP arranges for EU-GMP certification. EU-GMP provides the standards, principles and guidelines of good manufacturing practices for medicinal products used in the European Union and sets the minimum quality standard for cannabis for medical use. For Canadian licensed producers that do not meet EU-GMP standards, AMP and its German pharmaceutical consultants co-operate to identify the deficiencies, provide advice on how to meet the standards and conduct an audit upon completion of the upgrades. When the licensed producer passes the audit, AMP arranges for the final EU-GMP certification by German state officials. Upon final certification, AMP applies for the required import licences to Germany. If required, AMP may provide loan financing for EU-GMP upgrades.

By 2021, AMP plans to develop its own medical cannabis strains in collaboration with German patients, doctors and pharmacists for the German market.

AMP has raised $500,000 in equity and convertible debt financing in a Series A and Series B financings during 2018.

Other German investments

Mercury Partners is a public liability investment company based in Valletta, Malta, and has indirect investment holdings in German-listed securities and real-estate-related investments.

We seek Safe Harbor.